Analysis of the "off label" drug use in hematology and oncology
DOI:
https://doi.org/10.35509/01239015.32Keywords:
Off-Label Use, Medical Oncology, hematologyAbstract
Background and objective: the use of off-label drugs is the use of medications in conditions other than those included in its prescribing information. The objective of this paper is to analyze the off-label drugs applications and their results, performed by the Oncology and Hematology services in a second level hospital.
Materials and methods: A retrospective observational study of all requests for "off label" drugs received by the Pharmacy Service was carried out. The drugs were classified according to economic impact, a classification according to the type of drug and the reason for the request and according to the degree of evidence. The demographic, diagnostic and treatment data of the patients were analyzed for each request. A follow-up of adverse effects, median progression-free survival and median overall survival is presented.
Results: 85 treatment requests were approved. Most of the treatments were high impact, mainly aimed at rare pathologies and last treatment options. 22% of the requests had a high degree of evidence. Progression free survival (PFS) and overall survival (OS) were 6.6 (95% CI 5.2-8) and 9.7 months (95% CI 8.2-11.2). 18.7% of patients had grade 3-4 toxicity when receiving treatment.
Conclusions: Despite the heterogeneity of the pathologies, and the low evidence, the results obtained in SLP and SG, together with the low toxicity, force us to continue advancing in the evaluation of this type of treatments.
Author Biographies
María Antonia Meroño Saura, servicio de Farmacia Hospital Morales Meseguer
servicio de Farmacia Hospital Morales Meseguer, Murcia, España
María Dolores Nájera Pérez, servicio de Farmacia Hospital Morales Meseguer
servicio de Farmacia Hospital Morales Meseguer, Murcia, España
Francisco Ayala de la Peña, Hospital Morales Meseguer
servicio de Hematología y Oncología médica, Hospital Morales Meseguer, Murcia, España
Taida María Rodríguez Martínez, servicio de Farmacia Hospital Morales Meseguer
servicio de Farmacia Hospital Morales Meseguer, Murcia, España
Celia Fernández Zamora, servicio de Farmacia Hospital Morales Meseguer
servicio de Farmacia Hospital Morales Meseguer, Murcia, España
Josefa León Villar, servicio de Farmacia Hospital Morales Meseguer
servicio de Farmacia Hospital Morales Meseguer, Murcia, España
References
Real Decreto 1015/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. BOE núm. 174, de 20 de julio de 2009. p. 60904-60913.
Lerose, R., Musto, P., Aieta, M., Papa, C. & Tartarone, A. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur. J. Clin. Pharmacol. 68, 505–512 (2012).
Pérez-Moreno MA. Autorización de usos de medicamentos fuera de indicación en un hospital de tercer nivel. Calidad Asistencial 2013; 28 (1): 12-8
González – Haba E, Agustín MJ, Mangues I, Alfredo N, Fraga MD, Marín R et al. Uso de medicamentos fuera de ficha la técnica en oncohematología: resultado de una encuesta nacional. Farm Hosp. 2015; 39 (5).
Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: A systematic review of literature. J Clin Pharm Ther. 2017 Feb 5.
Stafford RD. Regulating Off-Label Drug Use — Rethinking the Role of the FDA. N Engl J Med. 2008; 358:1427-1429.
Kalis JA, Pence SJ, Mancini RS, Zuckerman DS, Ineck JR. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract. 2015;11(2):e139-43
Arroyo Álvarez C, Rodríguez Pérez L, Rodríguez Mateos ME, Martínez Bautista MJ, Benítez Rodríguez E, Baena-Cañada JM. Off-label antineoplastic drugs. An effectiveness and safety study. Farm Hosp. 2017;41(3):382-90.
Zarkali A, Karageorgopoulos DE, Rafailidis PI, Falagas ME. Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Curr Med Res Opin. 2014;30:471–80.
Shekelle P. Overview of clinical practice guidelines. Aronson MD, ed. UpToDate. Waltham, MA, 2018: UpToDate Inc. https://www.uptodate.com (Accessed on January 28, 2019.)
Eaton AA, Sima CS, Panageas KS. Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data. Journal of the National Comprehensive Cancer Network. 2016;14(1):57–65.
Cecchi M, Vaiani M, Ceroti M, Banfi R. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma. Int J Clin Pharm. 2013; 35(3):483–487
Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thuerlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol. 2014; 70:719–25
González – Haba E, Agustín MJ, Mangues I, Alfredo N, Fraga MD, Marín R et al. Uso de medicamentos fuera de ficha la técnica en oncohematología: resultado de una encuesta nacional. Farm Hosp. 2015; 39 (5).
Blanco-Reina E, Muñoz- García A, Cárdenas- Aranzana MJ, Ocaña-Riola R, Del Prado-Llergo JR. Assessment of off-label prescribing: profile, evidence and evolution. Farm.Hosp. 2017; 41 (4): 458 – 469.
Arroyo C, Rodríguez L, Rodríguez ME, Martínez MJ, Benítez E, Baena-Cañada JM. Off-label antineoplastic drugs. An effectiveness and safety study. Farm Hosp. 2017; 41(3):382-390.
Martín GA y cols. Quality of off-label prescriptions in advanced oncologic diseases. Med Clin 2015;145:178-9-DOI:10.1016/J.medcle.2014.09.010
Goločorbin Kon S, Iliković I, Mikov M Reasons for and frequency of off-label drug use. Med Pregl. 2015 Jan-Feb;68(1-2):35-40.
Green AK, Wood WA, Basch EM, et al. Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology. JAMA. 2016;316(15):1541-1542. doi:10.1001/jama.2016.12770 .
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
